Ozanimod, an oral selective sphingosine 1-phosphate (S1P) 1 and 5 receptor modulator, provided a favorable rate of long-term remission of ulcerative colitis (UC) relative to placebo in the maintenance phase of a multicenter Phase II trial.
The safety data were also encouraging, with similar rates of treatment-emergent adverse events on active therapy and placebo, according to the investigators, who presented the findings at the 2015 United European Gastroenterology Week (UEG; abstract